Home > Cardiology > Adding evolocumab to high-intensity statins in ACS patients reduces LDL-C substantially

Adding evolocumab to high-intensity statins in ACS patients reduces LDL-C substantially

Expert
Dr Konstantinos Koskinas, Bern University Hospital, Switzerland
Conference
ESC 2019
Trial
EVOPACS
The Swiss EVOPACS study showed that the PCSK9 antibody evolocumab added to high-intensity statin therapy in the very high-risk acute setting of acute coronary syndrome (ACS) resulted in a substantial reduction in LDL-C levels in patients. Treatment was safe, well tolerated, and raised no safety concerns. Lowering low-density lipoprotein (LDL)-C levels by treating ACS patients in the acute phase with high-intensity statins results in early (within 30 days) clinical benefit [1,2]. Proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies have also shown to lead to rapid, profound LDL-C reduction in patients without atherosclerotic cardiovascular disease (CV) or with stable/stabilised coronary artery disease (CAD) [3,4]. Dr Konstantinos Koskinas (Bern University Hospital, Switzerland) and colleagues set up the first randomised trial assessing the PCSK9 antibody evolocumab in the very high-risk acute setting of ACS. A total of 308 patients with s...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on